BGBIO possible bottomWe’re not there yet, but the downtrend seems to be exhausted.
Now a break of the downtrend (black arrow) AND the resistance area of NOK 20,50/21,- needs to happen and a potential W-formation is formed (see orange scenario).
Next report date
Report period
Q1 2024
EPS estimate
0.00USD
Revenue estimate
—
−0.0326USD
−30.80 MUSD
39.66 KUSD
1.27 B
About Bergenbio AS
Sector
CEO
Martin Olin
Headquarters
Bergen
Website
Employees (FY)
29
Founded
2007
ISIN
NO0010650013
FIGI
BBG00LGDWPS6
BerGenBio ASA engages in the development of biopharmaceutical product for cancer therapy. It focuses on developing a pipeline of AXL kinase inhibitors. Its lead product bemcentinib, is a selective and orally bio-available small molecule AXL inhibitor. The company was founded by James Bradley Lorens and David R. Micklem on December 21, 2007 and is headquartered in Bergen, Norway.
Just broke significant resistanceWe just broke significant resistance trend line (orange). Met first resistance at emission price at 37,50,-
The breakout has moved us closer to DNBs target at 68,-
BERGENBIO soon to break out?Price currently in a symmetrical triangle, making lower highs and higher lows. Expecting a breakout to the upside, if the price breaks out of the triangle.
Take profit 1: 45.90
Take profit 2: 51.85
Careful! if price breaks below the triangle, do not enter a trade. This stock is in an uptrend, an
BerGenBio trading plan for the next few daysThis is a trading plan based on price action. Keep in mind that BerGenBio will present updates on their current cancer treatment 25th june. This could boost the price extremely, because of the high volatility.
37.15 will be the safest price to enter a possible trade. That's why I am waiting for a
BGBIO - an intelligent bet on covidBGBIO is a biotech company with focus on cancer treatment.
Like most biotech it is extremely volatile for news, but often fluctuate between key buy and sell zones when no news are evident.
BGBIO is presenting news on their cancer treatment 25th of june.
They are currently first in line to do a fre
BGBIO / BergenBioBiotech company based i Norway/UK
Listed on OSE
BergenBio`s Bemcentinib now in
UK financed Covid-19 studym, Fast track ACCORD.
Number og study ongoing: 15
3 big:
* ACCORD Covid-19
* Bemcentinib/Keytruda combo whit Merck i NSCLC.
* AML
9 of 15 sponsored studies.
Tecnicaly potent, whit big up
BerGenBio $BGBIO upgraded target price to 86 NOK from ArcticSecQuote:
"Bemcentinib has shown effect against SARS-CoV-2 (coronavirus) in animal models and has been selected as the first of six drugs to be fast-tracked in the new UK initiative (ACCORD) to enter a phase 2 study directly.
Although there are many uncertainties around valuing this opportunity, we e
BerGenBio SMA50/200 golden cross tests breakout upon new dataABOUT BERGENBIO
OSL:BGBIO
BerGenBio is a clinical-stage oncology company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers.
www.bergenbio.com
www.nordnet.no
Trinity Del
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of BRRGF is 0.0250 USD — it has decreased by 98.59% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Bergenbio AS stocks are traded under the ticker BRRGF.
Bergenbio AS is going to release the next earnings report on May 29, 2024. Keep track of upcoming events with our Earnings Calendar.
BRRGF stock is 6.98 K% volatile and has beta coefficient of −1.48. Check out the list of the most volatile stocks — is Bergenbio AS there?
BRRGF earnings for the last quarter are 0.00 USD per share, whereas the estimation was 0.00 USD resulting in a 50.00% surprise. The estimated earnings for the next quarter are 0.00 USD per share. See more details about Bergenbio AS earnings.
Yes, you can track Bergenbio AS financials in yearly and quarterly reports right on TradingView.
BRRGF net income for the last quarter is −2.61 M USD, while the quarter before that showed −4.54 M USD of net income which accounts for 42.58% change. Track more Bergenbio AS financial stats to get the full picture.
Today Bergenbio AS has the market capitalization of 38.21 M, it has increased by 6.23% over the last week.
No, BRRGF doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, BRRGF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Bergenbio AS stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 26, 2024, the company has 29.00 employees. See our rating of the largest employees — is Bergenbio AS on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Bergenbio AS technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Bergenbio AS stock shows the strong sell signal. See more of Bergenbio AS technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Bergenbio AS future price: according to them, BRRGF price has a max estimate of 0.19 USD and a min estimate of 0.00 USD. Read a more detailed Bergenbio AS forecast: see what analysts think of Bergenbio AS and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Bergenbio AS EBITDA is −21.81 M USD, and current EBITDA margin is −81.02 K%. See more stats in Bergenbio AS financial statements.